Reference : Matrix metalloproteinase 12 silencing: A therapeutic approach to treat pathological l...
Scientific journals : Article
Human health sciences : Multidisciplinary, general & others
http://hdl.handle.net/2268/12062
Matrix metalloproteinase 12 silencing: A therapeutic approach to treat pathological lung tissue remodeling?
English
Garbacki, Nancy mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Protéines et glycoprot. de matr.extracell. et membran.basal. >]
Di Valentin, Emmanuel mailto [Université de Liège - ULg > > GIGA-R : Virologie - Immunologie >]
Piette, Jacques mailto [Université de Liège - ULg > Département des sciences de la vie > GIGA-R : Virologie - Immunologie - GIGA-Research >]
Cataldo, Didier mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path. >]
Crahay, Céline [ > > ]
Colige, Alain mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Protéines et glycoprot. de matr.extracell. et membran.basal. >]
2009
Pulmonary Pharmacology & Therapeutics
Academic Press
22
4
267-278
Yes (verified by ORBi)
International
1094-5539
London
United Kingdom
[en] siRNA delivery ; RNA interference; ; MMP-12 ; Asthma ; COPD ; Therapy
[en] Among the large matrix metalloproteinases (MMPs) family, MMP-12, also referred to as macrophage elastase, plays a significant role in chronic pulmonary pathologies characterized by an intense tissue remodeling such as asthma and COPD. This review will summarize knowledge about MMP-12 structure, functions and mechanisms of activation and regulation, including potential MMP-12 modulation by microRNA. As MMP-12 is involved in many tissue remodeling diseases, efforts have been made to develop specific synthetic inhibitors. However, at this time, very few chemical inhibitors have proved to be efficient and specific to a particular MMP. The relevance of silencing MMP-12 by RNA interference is highlighted. The specificity of this approach using siRNA or shRNA and the strategies to deliver these molecules in the lung are discussed.
http://hdl.handle.net/2268/12062
10.1016/j.pupt.2009.03.001

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Garbacki2009_MMP12.pdfNo commentaryPublisher postprint1.56 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.